HK1200700A1 - Formulations based on solid dispersions - Google Patents

Formulations based on solid dispersions

Info

Publication number
HK1200700A1
HK1200700A1 HK15101149.1A HK15101149A HK1200700A1 HK 1200700 A1 HK1200700 A1 HK 1200700A1 HK 15101149 A HK15101149 A HK 15101149A HK 1200700 A1 HK1200700 A1 HK 1200700A1
Authority
HK
Hong Kong
Prior art keywords
solid dispersions
formulations based
formulations
dispersions
solid
Prior art date
Application number
HK15101149.1A
Other languages
English (en)
Chinese (zh)
Inventor
Samuel Kyeremateng
Gerd Woehrle
Svenja Warnecke
Simon Kullmann
Ullrich Westedt
Jrgen Weis
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of HK1200700A1 publication Critical patent/HK1200700A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
HK15101149.1A 2011-09-26 2015-02-03 Formulations based on solid dispersions HK1200700A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11182792A EP2572731A1 (en) 2011-09-26 2011-09-26 Formulations based on solid dispersions
PCT/EP2012/068661 WO2013045365A1 (en) 2011-09-26 2012-09-21 Formulations based on solid dispersions

Publications (1)

Publication Number Publication Date
HK1200700A1 true HK1200700A1 (en) 2015-08-14

Family

ID=46875866

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101149.1A HK1200700A1 (en) 2011-09-26 2015-02-03 Formulations based on solid dispersions

Country Status (15)

Country Link
US (1) US20140296341A1 (xx)
EP (2) EP2572731A1 (xx)
JP (2) JP2014527976A (xx)
KR (1) KR20140069215A (xx)
CN (1) CN104039354B (xx)
AU (1) AU2012314661B2 (xx)
BR (1) BR112014006608A2 (xx)
CA (1) CA2847800A1 (xx)
CO (1) CO7071123A2 (xx)
HK (1) HK1200700A1 (xx)
IL (1) IL231384A0 (xx)
MX (1) MX2014003673A (xx)
RU (1) RU2014116987A (xx)
SG (1) SG11201400964PA (xx)
WO (1) WO2013045365A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090842A2 (en) * 2011-12-16 2013-06-20 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers
BR112016016021B1 (pt) * 2014-01-09 2023-01-10 Verastem, Inc. Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única
CN104857515B (zh) * 2014-02-25 2020-01-10 中国科学院上海药物研究所 一种控释给药的药芯组合物以及包含该药芯组合物的渗透泵制剂
CN105769753B (zh) * 2016-04-19 2019-10-29 浙江工业大学 一种温敏凝胶基质及其制备方法与应用
CN106937943A (zh) * 2017-04-20 2017-07-11 上药东英（江苏）药业有限公司 一种培哚普利及其盐的soluplus复合物固体分散体及其制备
DK3644970T3 (da) * 2017-06-30 2022-03-14 Acrotech Biopharma Llc Nye orale formuleringer af belinostat
JPWO2020027011A1 (ja) * 2018-07-30 2021-08-02 中外製薬株式会社 ヒダントイン誘導体の固体分散体
EP3886993A1 (en) * 2018-11-27 2021-10-06 Colgate-Palmolive Company Oral care implement having a release component

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE102005053066A1 (de) * 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2008037809A1 (en) * 2006-09-29 2008-04-03 Abbott Gmbh & Co. Kg Transmucosal administration of fibrate compounds and delivery system therefor
JP2010534730A (ja) 2007-07-26 2010-11-11 ビーエーエスエフ ソシエタス・ヨーロピア 溶液中でのグラフト重合により得られる、ポリエーテルに基づく固体形態のコポリマーの調製方法
US20110178183A1 (en) * 2008-09-25 2011-07-21 Meyer-Boehm Kathrin Use Of Polyether-Based And Vinyl Monomer-Based Copolymers As Binders For Dosing Forms Comprising Solid Active Ingredients
JP2012522029A (ja) * 2009-03-31 2012-09-20 ビーエーエスエフ ソシエタス・ヨーロピア 水に難溶性の物質の製剤を製造する方法
CN102458368B (zh) * 2009-05-13 2014-02-26 巴斯夫欧洲公司 含有基于聚醚的共聚物与微水溶性聚合物组合的固体药物制剂
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
US20120244197A1 (en) * 2009-11-24 2012-09-27 Basf Se Film-Like Pharmaceutical Dosage Forms
EP2536393B1 (en) * 2010-02-18 2014-04-16 AbbVie Deutschland GmbH & Co KG Test solvent for evaluating the compatibility of biologically active substances and graft copolymers

Also Published As

Publication number Publication date
IL231384A0 (en) 2014-04-30
EP2760474A1 (en) 2014-08-06
AU2012314661A1 (en) 2014-03-20
JP2017200938A (ja) 2017-11-09
KR20140069215A (ko) 2014-06-09
BR112014006608A2 (pt) 2017-04-25
JP2014527976A (ja) 2014-10-23
WO2013045365A1 (en) 2013-04-04
CN104039354B (zh) 2016-09-21
CN104039354A (zh) 2014-09-10
MX2014003673A (es) 2014-10-13
SG11201400964PA (en) 2014-04-28
AU2012314661B2 (en) 2017-08-03
US20140296341A1 (en) 2014-10-02
RU2014116987A (ru) 2015-11-10
NZ621872A (en) 2015-10-30
CO7071123A2 (es) 2014-09-30
EP2572731A1 (en) 2013-03-27
CA2847800A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
PT2765990T (pt) Dispersão sólida
GB201111438D0 (en) Formulation
HK1189834A1 (zh) 基於固體分散體的固體延緩配方
AP3879A (en) An improved herbicidal formulation
ZA201309221B (en) Formulation
HK1200700A1 (en) Formulations based on solid dispersions
EP2753311A4 (en) ANTIOXIDATIVE FORMULATIONS
IL230305A (en) Milk-based compound
ZA201402456B (en) Formulation
HRP20151339T8 (xx) Pripravak baziran na ubidekarenonu
GB201110278D0 (en) Formulations
GB201106958D0 (en) Formulation
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201109554D0 (en) Quick hitch
GB201104284D0 (en) Formulation
AU2012905689A0 (en) Imaging agents
AU2011905352A0 (en) Imaging agents